Kohjin Bio Co., Ltd.

TSE:177A Stock Report

Market Cap: JP¥8.6b

Kohjin Bio Valuation

Is 177A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 177A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 177A (¥1676) is trading above our estimate of fair value (¥335.44)

Significantly Below Fair Value: 177A is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 177A?

Key metric: As 177A is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 177A. This is calculated by dividing 177A's market cap by their current earnings.
What is 177A's PE Ratio?
PE Ratio22.3x
EarningsJP¥384.00m
Market CapJP¥8.57b

Price to Earnings Ratio vs Peers

How does 177A's PE Ratio compare to its peers?

The above table shows the PE ratio for 177A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.9x
2929 Pharma Foods International
8.5xn/aJP¥28.0b
4974 Takara Bio
139.1x26.0%JP¥126.4b
2160 GNI Group
23.7x23.9%JP¥170.6b
4587 PeptiDream
20x0.1%JP¥342.8b
177A Kohjin Bio
22.3x25.7%JP¥8.6b

Price-To-Earnings vs Peers: 177A is good value based on its Price-To-Earnings Ratio (22.3x) compared to the peer average (47.9x).

Price to Earnings Ratio vs Industry

How does 177A's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
177A 22.3xIndustry Avg. 29.3xNo. of Companies11PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 177A is good value based on its Price-To-Earnings Ratio (22.3x) compared to the Asian Biotechs industry average (29.4x).

Price to Earnings Ratio vs Fair Ratio

What is 177A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

177A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.3x
Fair PE Ratio18.3x

Price-To-Earnings vs Fair Ratio: 177A is expensive based on its Price-To-Earnings Ratio (22.3x) compared to the estimated Fair Price-To-Earnings Ratio (18.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 14:29
End of Day Share Price 2024/12/30 00:00
Earnings2024/03/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kohjin Bio Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyoichiro ShigemuraNomura Securities Co. Ltd.